Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of PLA2 (unknown origin)
Assay data:9 Active, 2 Activity ≤ 1 µM, 14 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human group IB phospholipase A2 expressed in Escherichia coli BL21 cells incubated for 10 to 20 mins cells by radiometric assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human group IB phospholipase A2 incubated for 1 hrs by scintillation counter analysis
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
Inhibition of human non pancreatic secretory phospholipase A2 incubated for 30 mins by plate reader analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
sPLA2-V activity assay from Article 10.1111/cbdd.12280: "Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2 , cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin E synthase-1."
Assay data:3 Active, 1 Activity ≤ 1 µM, 18 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
Phospholipase A2 Vesicle Assay from Article : "Inhibition studies on the membrane-associated phospholipase A2 in vitro and prostaglandin E2 production in vivo of the macrophage-like P388D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide."
Assay data:4 Tested
In Vitro Colorimetric Enzyme Assay from Article 10.1002/cbic.200390029: "D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity."
Assay data:18 Active, 14 Activity ≤ 1 µM, 18 Tested
Inhibition of PLA2 (unknown origin) using soybean phosphatidylcholine as substrate at 3 uM preincubated for 30 mins followed incubated for 60 mins after substrate addition by microplate reader relative to control
Assay data:2 Tested
Inhibition of PLA2 (unknown origin) using soybean phosphatidylcholine as substrate preincubated for 30 mins followed incubated for 60 mins after substrate addition by microplate reader relative to control
Inhibition of PLA2 (unknown origin) using soybean phosphatidylcholine as substrate at 10 uM preincubated for 30 mins followed incubated for 60 mins after substrate addition by microplate reader relative to control
Assay data:6 Tested
Inhibition of sPLA2 in atherosclerotic plaque from coronary artery disease patient
Inhibition of sPLA2 in human HepG2 cells
Inhibition of sPLA2 in human plasma at 25 uM using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay
Inhibition of sPLA2 in human plasma using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay
Assay data:9 Active, 4 Activity ≤ 1 nM, 9 Activity ≤ 1 µM, 11 Tested
Ratio of XI50 for inhibition of human recombinant sPLA2 using PAPG to XI50 for inhibition of human recombinant sPLA2 using PAPC
Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in free FA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human recombinant sPLA2 using PAPS as substrate assessed as reduction in 16:0 LPS formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPG as substrate assessed as reduction in 16:0 LPG formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPE as substrate assessed as reduction in 16:0 LPE formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Inhibition of human recombinant sPLA2 using PAPC as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on